Table 2 ROC for diagnosing proliferative LN among SLE patients with various urinary cell types as markers
Examined marker | Patients | Controls | Area under the ROC curve | Cutoff | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
(n =) | (n =) | (%) | (%) | |||
uCD3 + CD8+ | 17 | 55 | 1.0000 | >650 cells/dl | 100 | 100 |
uCD3 + CD4+ | 19 | 55 | 0.9982 | >270 cells/dl | 100 | 98.25 |
CCR7-CD45RO+ | 6 | 34 | 0.9832 | >300 cells/dl | 100 | 94.12 |
CCR7 + CD45RO+ | 6 | 34 | 0.8172 | >35 cells/dl | 85.71 | 79.41 |
CCR7 + CD45RO- | 6 | 34 | 0.7941 | >45 cells/dl | 100 | 52.94 |
CD40l+ | 6 | 34 | 0.9706 | >100 cells/dl | 100 | 70.59 |
CD127-FoxP3+ | 7 | 13 | 0.9017 | >5 cells/dl | 77.78 | 84.44 |
Proteinuria | 16 | 45 | 0.9201 | >620 mg/d | 93.75 | 83.87 |
uCD14+ | 17 | 31 | 0.9066 | >1700 cells/dl | 94.74 | 83.87 |
uCD19+ | 10 | 31 | 0.7823 | >75 cells/dl | 90 | 70.97 |
Creatinine | 19 | 55 | 0.6031 | >1.1 mg/dl | 47.37 | 79.17 |